CLAIMS

1. Use of an isolated peptide and a pharmaceutically acceptable carrier in the manufacture of a medicament for preventing, treating, ameliorating or managing cancer or a neoplastic disorder, wherein the medicament consists essentially of the isolated peptide and the pharmaceutically acceptable carrier, and wherein the isolated peptide:

(a) comprises an amino acid sequence of WEHVNAIQEARRLL (SEQ ID NO: 114), wherein the isolated peptide is not more than 29 amino acids in length; or

(b) consisting essentially of an amino acid sequence of WEHVNAIQEARRLL (SEQ ID NO: 114), wherein one amino acid residue of the amino acid sequence is replaced with an amino acid substitution or an amino acid equivalent.

2. Use of an isolated peptide and a pharmaceutically acceptable carrier in the manufacture of a pharmaceutical composition for preventing, treating, ameliorating or managing cancer or a neoplastic disorder, wherein the isolated peptide:

(a) comprises an amino acid sequence of WEHVNAIQEARRLL (SEQ ID NO: 114), wherein the isolated peptide is not more than 29 amino acids in length; or

(b) consisting essentially of an amino acid sequence of WEHVNAIQEARRLL (SEQ ID NO: 114), wherein one amino acid residue of the amino acid sequence is replaced with an amino acid substitution or an amino acid equivalent.

3. Use of a pharmaceutical composition consisting essentially of an isolated peptide and a pharmaceutically acceptable carrier in the manufacture of a medicament for preventing, treating, ameliorating or managing cancer or a neoplastic disorder, wherein the isolated peptide:

(a) comprises an amino acid sequence of WEHVNAIQEARRLL (SEQ ID NO: 114), wherein the isolated peptide is not more than 29 amino acids in length; or

(b) consisting essentially of an amino acid sequence of WEHVNAIQEARRLL (SEQ ID NO: 114), wherein one amino acid residue of the amino acid sequence is replaced with an amino acid substitution or an amino acid equivalent.

4. The use of any one of claims 1-3, wherein the isolated peptide comprises an amino acid sequence of WEHVNAIQEARRLL (SEQ ID NO: 114), wherein the isolated peptide is not more than 29 amino acids in length.

5. The use of any one of claims 1-3, wherein the isolated peptide comprises an amino acid sequence consisting of WEHVNAIQEARRLL (SEQ ID NO: 114).

6. The use of any one of claims 1-3, wherein the isolated peptide consisting essentially of an amino acid sequence of WEHVNAIQEARRLL (SEQ ID NO: 114), wherein one amino acid residue of the amino acid sequence is replaced with an amino acid substitution or an amino acid equivalent.

7. The use of claim 6, wherein one amino acid residue of the amino acid sequence is replaced with a conservative amino acid substitution.

8. The use of claim 6, wherein one amino acid residue of the amino acid sequence is replaced with a non-conservative amino acid substitution.

9. The use of claim 6, wherein one amino acid residue of the amino acid sequence is replaced with an amino acid equivalent.

10. The use of any one of claims 1-9, wherein the isolated peptide is modified with an addition of polyethylene glycol.

11. The use of any one of claims 1-10, wherein the cancer or neoplastic disorder is of the central nervous system, peripheral nervous system, gastrointestinal system, digestive system, genitourinary system, gynecological system, head and neck, hematological system, blood, musculoskeletal tissue, soft tissue, respiratory system or breast.

12. The use of claim 11, wherein the cancer or neoplastic disorder is of the digestive system.

13. The use of claim 12, wherein the cancer or neoplastic disorder of the digestive system is selected from the group consisting of appendix cancer, bile duct cancer, colon cancer, gallbladder cancer, gastric cancer, intestinal cancer, colon cancer, liver cancer, pancreatic cancer, rectal cancer, and stomach cancer.

14. The use of claim 10, wherein the cancer or neoplastic disorder is of the respiratory system.

15. The use of claim 14, wherein the cancer or neoplastic disorder of the respiratory system is lung cancer.

16. The use of claim 15, wherein the lung cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, squamous cell lung cancer and mesothelioma.

17. The use of claim 16, wherein the non-small cell lung cancer is adenocarcinoma.